Indeed, the anti-Id Hc5 scFv was able to capture circulating SM03 and successfully used to delineate the PK profiles of different lymphoma patients treated with SM03 in a phase I dose-escalation clinical study [13]. This evidence concerns the gene ID1 and lymphoma.